Metronidazole for Clostridium difficile-associated disease: Is it okay for mom?

Clinical Infectious Diseases

Volumn 40, Issue 11, 2005, Pages 1598-1600

  Gerding, Dale N ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; FUSIDIC ACID; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFAXIMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; DISEASE PREDISPOSITION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE DELETION; HOSPITAL INFECTION; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MOTHER; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE;

ANTI-BACTERIAL AGENTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; RECURRENCE; VANCOMYCIN;

EID: 19344363058     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430317     Document Type: Note

References (14)

1. Bartlett JG. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89:1192-4.
2. Gorbach SL. Drugs for your mother-in-law, not your mother. Infect Dis Clin Pract 1992; 1:46.
3. Barza M. Metronidazole for Clostridium difficile: still only for your mother-in-law? Infect Dis Clin Pract 1997; 6:211.
4. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
5. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16:105-13 (erratum: Infect Control Hosp Epidemiol 1995; 16:498).
6. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998; 55:1407-11.
7. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005:CD004610.
8. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90 (in this issue).
9. Pépin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7 (in this issue).
10. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
11. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers with vancomycin, metronidazole, or placebo. Ann Intern Med 1992; 117:297-302.
12. Davidson D, Peppe J, Louie T, et al. A phase 2 study of the toxin binding polymer tolevamer in patients with C. difficile-associated diarrhea. In: Program and abstracts of the 14th European Congress on Clinical Microbiology and Infectious Diseases (Prague, Czech Republic). 2004.
13. Pullman J, Prieto J, Leach TS. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). 2004.
14. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.